This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU) (PKU&DHA)

This study has been completed.
Atlanta Clinical and Translational Science Institute
Information provided by (Responsible Party):
Rani Singh, Emory University Identifier:
First received: May 1, 2009
Last updated: December 9, 2015
Last verified: December 2015
The purpose of this study is to determine if taking supplemental DHA improves measures of processing speed and executive function in teen and adult women with PKU.

Condition Intervention
Phenylketonuria Dietary Supplement: Docosahexaenoic Acid Dietary Supplement: Corn/soy oil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With Phenylketonuria

Resource links provided by NLM:

Further study details as provided by Rani Singh, Emory University:

Primary Outcome Measures:
  • Cognitive processing speed [ Time Frame: 0 months, 4.5 months ]
  • Executive function [ Time Frame: 0 months, 4.5 months ]

Secondary Outcome Measures:
  • Plasma and red blood cell DHA concentrations [ Time Frame: 0 months, 4.5 months ]

Enrollment: 33
Study Start Date: June 2007
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DHA supplementation Dietary Supplement: Docosahexaenoic Acid
Capsules providing 10 mg DHA/kg body weight/day taken once daily
Other Name: DHASCO-S
Placebo Comparator: corn/soy capsule, no DHA Dietary Supplement: Corn/soy oil
Capsules taken once daily


Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females
  • Phenylketonuria
  • Ages 12 years and older
  • Able to complete neuropsychological testing

Exclusion Criteria:

  • Pregnancy
  • Currently taking DHA supplement
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00892554

United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Atlanta Clinical and Translational Science Institute
Principal Investigator: Rani H. Singh, PhD, RD, LD Emory University
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rani Singh, Professor, Emory University Identifier: NCT00892554     History of Changes
Other Study ID Numbers: IRB00002447
Study First Received: May 1, 2009
Last Updated: December 9, 2015

Keywords provided by Rani Singh, Emory University:
Docosahexaenoic Acids
Neuropsychological Tests

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases processed this record on September 21, 2017